Janssen launches development of Tremfya for rare intestinal polyp disorder

|About: MorphoSys AG (MOR)|By:, SA News Editor

Morphosys AG (NASDAQ:MOR) announces that licensee Janssen Biotech has expanded development of Tremfya (guselkumab) into familial adenomatous polyposis (FA), an inherited disorder characterized by polyps in the colon that lead to cancer.

Janssen has initiated a Phase 1b proof-of-concept study that will enroll about 72 FAP patients.

Tremfya, an interleukin-23 inhibitor, is currently approved in the U.S., Europe, Canada and certain other markets for plaque psoriasis and in Japan for several types of psoriasis, psoriatic arthritis and palmoplantar pustulosis.

Subscribe for full text news in your inbox